Formulary Watch |

FDA approved the first generic of a popular inhaler to treat asthma and chronic obstructive pulmonary disease

CVS Health adds new migraine drugs to its list of covered drugs, but excludes one rival treatment.

FDA approves cabozantinib to treat patients with hepatocellular carcinoma, a community in need of new therapeutic options.

A new report details the financial strain rising drug prices are having on patients and hospitals alike.

FDA cleared the first generic tablet version of a top-selling epilepsy drug.

New legislation designed to curb drug costs comes on the heels of many pharma makers raising prices this year as well as payers saying they expect higher drug acquisition costs.

FDA approved a record number of novel treatments in 2018.

Soon after FDA warned the manufacturer involved in a massive nationwide recall of valsartan- and losartan-containing drugs, the recall is expanding. Find out why.

Two new therapies approved by FDA signal significant advancement in treating rare blood diseases.

Fluoroquinolone antibiotics can increase the occurrence of rare but serious events of ruptures or tears in the aorta, FDA said in a new warning.

 A new non-small cell lung cancer (NSCLC) treatment is available to healthcare providers immediately.  

After an expanded recall of the blood pressure medication valsartan, FDA is warning the manufacturer of the carcinogenic ingredient involved.

Two major drug recalls in the last week include an expanded recall of a widely used blood pressure medication as well as over-the-counter infant ibuprofen.

Find out how healthcare organizations and analysts feel about new Medicare Part D proposals and drug pricing.

Here are the top 2 novel cancer drugs cleared by the agency.

FDA approved the first biosimilar to rituximab (Rituxan, Genentech) to treat non-Hodgkin lymphoma.

FDA approved an autoinjector to treat rheumatoid arthritis and other diseases. 

While some pharma makers have lowered drug prices and Express Scripts is pushing more branded manufacturers to lower list prices with its new National Preferred Flex Formulary, some manufacturers are raising drug prices.

Express Scripts’ new National Preferred Flex Formulary, which offers lower list prices on certain branded drugs, is a novel way to encourage pharma makers to lower prices.

Despite concerns about a new opioid that is reportedly 1,000 times more powerful than morphine, FDA recently approved the new painkiller.

Certain groups expressed “deep concern” over FDA allowing an OTC asthma inhaler to be sold again after it was removed from the market 7 years ago. Here’s why.

FDA approves the first new flu drug in 20 years. Here’s what’s different about it.

A pharma maker is voluntarily recalling several lots of a major heart medication. Here’s why.

FDA recently stopped importation and sent warning letters to numerous online sellers of illegal opioids, oncology drugs and other medicines.

Pharmacy benefit managers, cardiologists, and others praised a pharma maker for significantly reducing the price of its high cholesterol drug.

A novel treatment for patients with moderate-to-severe asthma is now on the market.

A new indication for rivaroxaban (Xarelto) has been approved by FDA.

FDA approved a new antibiotic to treat community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).